Marinus Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview

Marinus Pharmaceuticals

01/03/2024 21:04

* Marinus Pharmaceuticals Inc  MRNS.OQ   MRNS.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 5 for the period ending December 31 2023
    * The Radnor Pennsylvania-based  company is expected to
report a
11.9% increase in revenue to $8.015 million from $7.16 million a
year ago, according to the mean estimate from 11 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Marinus Pharmaceuticals
Inc is
for a loss of 62 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $21.00​, above​ its last closing price
of $9.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.65       -0.66      -0.61     Beat    7.7
 Jun. 30 2023  -0.69       -0.72      -0.61     Beat    14.9
 Mar. 31 2023  -0.71       -0.72      -0.67     Beat    7.3​
 Dec. 31 2022  -0.66       -0.70      -0.76     Missed  -9.1
 ​​Sep.        0.54        0.47       -0.94     Missed  -301.2
 30 2022                                                
 Jun. 30 2022  -0.64       -0.69      -1.06     Missed  -54.7​
 Mar. 31 2022  -0.85       -0.85      -0.52     Beat    38.8
 Dec. 31 2021  -0.72       -0.76      -0.77     Missed  -1.2
 This summary was machine generated March 1 at 21:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)